Health Trials

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

ConditionsRelapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal Large B-Cell Lymphoma (PMBCL)High-grade B-cell LymphomaTransformed Follicular Lymphoma (TFL)ALL (Acute B-Lymphoblastic Leukemia)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorCurocell Inc.

About this trial

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

Eligibility criteria

Qualifiers

≥ 19 years of age and provided written informed consent

Histologically confirmed following large B-cell lymphomas according to the World Health Organization classification 2017

Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma)

High-grade B-cell lymphoma, not otherwise specified

Disqualifiers

Patients with the following medical history

Adequately treated basal cell or squamous cell carcinoma without evidence of recurrence for at least 3 years prior to the study

In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study

A primary malignancy which has been completely resected and in complete remission for ≥ 5 years

Trial design

Treatments tested in this trial

  • CRC01
  • Fludarabine
  • Cyclophosphamide

Treatment groups

91 Participants
are divided into 1 treatment group

Sponsors and collaborators

Curocell Inc.

Lead sponsor

Source ClinicalTrials.gov